Efficacy of dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes undergoing hemodialysis by Yuichi Terawaki et al.
METABOLIC SYNDROME
DIABETOLOGY & 
Terawaki et al. Diabetology & Metabolic Syndrome  (2015) 7:44 
DOI 10.1186/s13098-015-0043-2RESEARCH Open AccessEfficacy of dipeptidyl peptidase-4 inhibitor
linagliptin in patients with type 2 diabetes
undergoing hemodialysis
Yuichi Terawaki1, Takashi Nomiyama1*, Hiroyuki Takahashi1, Yoko Tsutsumi1, Kunitaka Murase1, Ryoko Nagaishi1,
Makito Tanabe1, Tadachika Kudo2, Kunihisa Kobayashi2, Tetsuhiko Yasuno3, Hitoshi Nakashima3 and Toshihiko Yanase1Abstract
Background: Incretin therapy is feasible in patients with type 2 diabetes mellitus undergoing hemodialysis (HD).
However, few studies have examined the safety and efficacy of this therapeutic approach in patients with diabetes
and renal impairment. Here, we examined glycemic control and the anti-oxidative-stress effects of the dipeptidyl
peptidase (DPP)-4 inhibitor linagliptin in patients with type 2 diabetes undergoing HD.
Methods: Thirty-five patients with type 2 diabetes undergoing HD (including 13 insulin-treated patients) were
switched from ongoing therapy to linagliptin (5 mg, once daily). Levels of fasting blood glucose, C-peptide
immunoreactivity (CPR), glycated albumin, B-type natriuretic peptide, oxidized low-density lipoprotein (oxLDL),
high-sensitivity C-reactive protein, 8-hydroxy-2′-deoxyguanosine (8OHdG), body mass index, blood pressure, and
other biologic characteristics (liver function, renal function, lipid profile) were determined before and 3 months
after linagliptin treatment. Patients were classified into insulin-treated and non-insulin groups.
Results: With the exception of levels of total bilirubin, aspartate aminotransferase, and CPR, none of the patients
exhibited changes in glucose metabolism after switching to linagliptin treatment. However, oxLDL levels were
decreased significantly by linagliptin therapy in the non-insulin-treated group despite the absence of changes in
glycemic control.
Conclusion: Linagliptin can decrease serum levels of oxLDL in patients with type 2 diabetes undergoing HD
independent of its glucose-lowering effect.
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Diabetes mellitus is a multifactorial progressive disease
accompanied by the development of systematic vascular
complications, one of the most important of which is
diabetic nephropathy. Diabetic nephropathy results in
severe renal failure, which necessitates hemodialysis
(HD). Indeed, diabetic nephropathy has been the leading
cause of the requirement for HD in Japan since 1998.
Controlling glucose levels in the blood of diabetic pa-
tients with severe renal failure is difficult because of:
frequent hypoglycemia; restrictions in the use of anti-* Correspondence: tnomiyama@fukuoka-u.ac.jp
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unless otherwise stated.diabetic agents; the instability of glucose, insulin, and
drug metabolites on the days when the patient does not
receive HD.
Previously, we have reported the efficacy of incretin
therapy using continuous monitoring of glucose in pa-
tients with type 2 diabetes undergoing HD [1]. However,
one of the most important causes of death in patients
undergoing HD is cardiovascular disease. Lowering the
glomerular filtration rate in patients with chronic kidney
disease increases oxidative stress [2]. This action increases
the risk of cardiovascular disease, primarily through in-
activation of nitric oxide and production of oxidized
low-density lipoprotein (oxLDL) [3]. Thus, patients with
type 2 diabetes undergoing HD must be administeredal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Patient characteristics at baseline
Parameters Mean ± SE
Age (years) 65.4 ± 1.9
Male/female 15:20
Duration of diabetes (years) 20.1 ± 1.8
Duration of HD (years) 3.5 ± 0.4
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vascular-protective effects.
Incretins such as glucagon-like peptide (GLP)-1 and
glucose-dependent insulinotropic polypeptide have been
reported not only to act on pancreatic β-cells to stimulate
glucose-responsive insulin secretion, but also to provide
tissue-protective effects beyond lowering of blood glucose
[4]. The dipeptidyl peptidase (DPP)-4 inhibitor linagliptin
has been approved for use in patients with declining renal
function at the same dose as that administered to patients
with normal renal filtration owing to its primarily hepato-
biliary route of elimination from the body. Furthermore,
the safety and efficacy of linagliptin in patients with dia-
betes and severe renal impairment have been reported [5].
Interestingly, a retrospective analysis revealed that lina-
gliptin reduced cardiovascular events compared with
other glucose-lowering agents [6]. Several studies have
investigated the vascular-protective effects of linagliptin
via incretin-dependent and incretin-independent mech-
anisms. These effects include anti-oxidative stress [7],
inhibition of advanced glycation end-products (AGE)
and their receptor (RAGE) axis [8], inhibition of vascular
DPP-4 activity [9], and cardioprotection [10]. Furthermore,
we have reported that linagliptin attenuates neointima
formation after vascular injury through its anti-
oxidative-stress effects [11]. Thus, these data suggest
the anti-oxidative stress and vascular-protective effects
of linagliptin.
However, there are no reports describing the anti-
oxidative stress and vascular-protective effects of lina-
gliptin in patients with type 2 diabetes undergoing HD.
In the present study, we examined glycemic control and
a marker of the anti-oxidative-stress effect of linagliptin
in patients with type 2 diabetes undergoing HD.
Methods
Thirty-five Japanese patients with type 2 diabetes under-
going HD (including 13 insulin-treated patients) aged
44–82 years were recruited to the study. Patients receiving
anti-diabetic treatment were switched to linagliptin (5 mg,
once daily) for 3 months. Some insulin-treated patients
were hospitalized and switched to linagliptin, as reported
previously [1]. Patients with a history of type 1 diabetes
and diabetic ketoacidosis, impairment of intrinsic in-
sulin secretion (fasting serum C-peptide immunoreactivity
(CPR) < 2.0 ng/dL), severe cardiac disease (New York
Heart Association grade ≥ III), or severe liver disease
were excluded.
The following efficacy parameters were examined be-
fore and 3 months after treatment: fasting blood glucose
(BG), CPR, glycated albumin (GA), B-type natriuretic
peptide (BNP), oxLDL, high-sensitivity C-reactive pro-
tein (hsCRP), 8-hydroxy-2′-deoxyguanosine (8OHdG),
body mass index, blood pressure, and other biologicalexaminations (total protein, albumin, aspartate amino-
transferase (AST), alanine aminotransferase (ALT), γ-
glutamyl transpeptidase (γGTP), total bilirubin, alkaline
phosphatase (ALP), lactate dehydrogenase (LDH), blood
urea nitrogen (BUN), creatinine, total cholesterol, low-
density lipoprotein-cholesterol (LDL-C), high-density
lipoprotein-cholesterol (HDL-C), triglyceride). GA is a
more reliable marker of glycemic control than glycated
hemoglobin in patients with renal failure [12], so GA
was measured as a marker of glycemic control in the
present study. Blood samples were taken before the
start and 3 months after linagliptin treatment when pa-
tients visited the clinic to receive HD. Serum levels of
oxLDL (normal range for males < 45 years and females <
55 years: 46–82 U/L; normal range for males ≥ 45 years and
females ≥ 55: 61–105 U/L) and 8OHdG were measured
using an enzyme immunoassay at SRL Inc. (Tokyo, Japan).
Other parameters were measured by staff in relevant
departments within each hospital.
Baseline characteristics of the 35 patients are shown in
Table 1. Mean duration of diabetes was 20.1 ± 1.8 years.
Mean duration of HD was 3.5 ± 0.4 years. Of these 35
patients, seven patients had not received anti-diabetic
drugs, eight patients received incretin therapy (four re-
ceived DPP-4 inhibitors and four received liraglutide),
eight patients received other anti-diabetic drugs, and 13
received insulin therapy (17.4 ± 2.3 U/day). None of the
patients were treated with an anti-glutamic acid de-
hydrogenase antibody and none had a history of ketoaci-
dosis. All patients were treated thrice weekly for 4–5 h
with a bicarbonate dialysate containing 100 mg/dL of
glucose. Eight patients were taking statins at baseline,
and continued taking them during the study period. No
patient received new anti-diabetic and anti-dyslipidemia
agents during the study period.
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participate in this study. The protocol was approved by
the Ethics Committees of Fukuoka University Hospital
(Fukuoka, Japan). The study was carried out in accordance
with the ethical principles of the Declaration of Helsinki
(1964) amended in Edinburgh in 2000. The study protocol
was registered as UMIN (ID: 000007716).
Paired t-tests were undertaken for statistical analyses
as appropriate. P < 0.05 was considered significant. Re-
sults are the mean ± standard error of the mean.Results
No episodes of severe hyperglycemia, ketosis, severe
nausea, or other adverse effects were observed in pa-
tients at any time during linagliptin treatment. La-
boratory data before and after treatment in all patients
are shown in Table 2. Serum levels of AST and total
bilirubin were decreased significantly by linagliptin
treatment, but these changes were within the normal
range and not clinically significant. Serum levels ofTable 2 Comparison of all patients before and after treatment
Parameter Before After
BMI (kg/m2) n = 30 23.0 ± 0.8 23.0 ± 0.8
Systolic blood pressure (mmHg) n = 31 150.0 ± 5.0 159.4 ± 4.2
Diastolic blood pressure (mmHg) n = 31 73.1 ± 3.0 76.3 ± 2.6
Total protein (g/dL) 6.5 ± 0.1 6.6 ± 0.1
Albumin (g/dL) n = 34 3.7 ± 0.1 3.8 ± 0.1
AST (U/L) 15.1 ± 0.8 13.4 ± 0.8*
ALT (U/L) n = 34 12.0 ± 1.0 10.1 ± 1.1
γGTP (U/L) 22.5 ± 2.5 23.4 ± 4.2
Total bilirubin (mg/dL) n = 29 0.35 ± 0.02 0.28 ± 0.02*
ALP (U/L) n = 34 257.4 ± 23.6 265.1 ± 22.0
LDH (U/L) n = 34 189.6 ± 5.9 183.3 ± 5.7
BUN (mg/dL) 54.7 ± 1.7 54.0 ± 2.0
Creatinine (mg/dL) 8.27 ± 0.32 8.32 ± 0.38
Total cholesterol 159.0 ± 6.0 155.5 ± 5.4
LDL-C (mg/dL) n = 34 83.1 ± 4.1 80.3 ± 3.8
HDL-C (mg/dL) 47.1 ± 2.8 48.8 ± 2.9
Triglyceride (mg/dL) n = 33 120.7 ± 7.7 124.4 ± 8.9
GA (%) 21.9 ± 0.6 22.7 ± 0.9
CPR (ng/mL) n = 32 9.39 ± 0.89 10.73 ± 0.94*
BG (mg/dL) 167.0 ± 7.1 162.7 ± 6.9
BNP (ng/mL) n = 32 405.5 ± 88.6 410.4 ± 90.8
oxLDL (U/L) n = 33 98.4 ± 5.1 91.6 ± 5.2
hsCRP (mg/dL) n = 30 0.204 ± 0.056 0.187 ± 0.056
8OHdG (ng/mL) n = 17 0.344 ± 0.021 0.338 ± 0.031
*P < 0.05 compared with before treatmentCPR were increased significantly by linagliptin treatment.
In addition, there were no differences in levels of BG, GA,
BNP, oxLDL, hsCRP, and 8OHdG, or lipid profiles,
measured before and after treatment for all patients.
Insulin is the most effective glucose-lowering agent, so
switching from insulin to linagliptin increased GA levels
in patients (Fig. 1A). Furthermore, reports have strongly
suggested that hyperglycemia is a major mediator of oxi-
dative stress in patients with diabetes through several
mechanisms, such as stimulation of the polyol pathway
[13], activation of protein kinase C [14], increased levels
of glycated superoxide dismutase [15], and overproduction
of superoxide in mitochondria [16]. Thus, to eliminate the
glucose-lowering effects of insulin therapy, we further ex-
amined the efficacy of linagliptin in non-insulin-treated
patients (n = 22).
To evaluate the anti-oxidative effects of linagliptin be-
yond its glucose-lowering effect, we re-analyzed data in
patients who had not been treated with insulin previ-
ously as the “non-insulin group” (which included the
non-treated group and non-insulin-treated group). La-
boratory data (including GA) in non-insulin patients
measured before and after switching to linagliptin are
shown in Table 3, and oxLDL levels are shown in Fig. 1B.
GA levels were not decreased by linagliptin treatment in
the non-insulin-treated group, whereas levels of total
cholesterol, LDL-C, and oxLDL were decreased signifi-
cantly. Serum levels of total bilirubin were decreased sig-
nificantly by linagliptin treatment. However, these
changes were within the normal range and similar data
were obtained for all patients, so these changes were not
clinically significant.
Other incretin therapies have also been reported to
have anti-oxidative-stress effects [17]. To ascertain if
lowered levels of oxLDL could be a characteristic effect
of linagliptin, we compared oxLDL levels in patients ac-
cording to whether or not they had been treated with
incretin. Because of the small number of patients, we
could not observe a significant change. oxLDL levels were
decreased in eight incretin-treated patients (99.4 ± 8.2
to 90.3 ± 6.5 U/L) and 27 non-incretin-treated patients
(98.0 ± 6.0 to 92.0 ± 6.3 U/L), independent of GA levels
(incretin-treated: 21.8 ± 1.4 % to 21.7 ± 1.5 %; non-incretin-
treated: 21.9 ± 0.7 % to 23.0 ± 1.0 %).
Discussion
The present study demonstrated that linagliptin de-
creased serum levels of oxLDL in patients with type 2
diabetes undergoing HD independent of its glucose-
lowering effect. LDL-C is readily oxidized in patients
with diabetes [18]. In addition, oxLDL is an important
factor for predicting cardiovascular disease in patients
with diabetes [19]. Oxidative stress is increased if acute
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Fig. 1 Levels of glycated albumin (GA) and oxidized low-density lipoprotein (oxLDL) in insulin-treated and non-insulin-treated groups measured
before and after treatment. a GA levels in the non-treated group (n = 7), non-insulin-treated group (n = 16) and the insulin-treated group (n = 12).
b Serum levels of oxLDL in the non-insulin group (n = 22) and insulin-treated group (n = 11). Data are the mean ± standard error of the mean.
*P < 0.05 vs. values before treatment
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mean amplitude of glucose excursion, urinary levels of
8-iso prostaglandin F2α, and a marker of oxidative stress
has been reported [20]. DPP-4 inhibitors mainly target
postprandial hyperglycemia and glucose fluctuations
[21]. Therefore, we suggest that linagliptin decreases
oxidative stress by inhibiting hyperglycemia and glu-
cose fluctuations (though the latter parameter was not
evaluated in the present study). Serum levels of active
GLP-1 have been shown to be increased significantly
in linagliptin-treated patients with type 2 diabetes
undergoing HD [22]. In addition, the GLP-1 receptor
agonist liraglutide has been demonstrated to decrease
oxidative stress independent of its glucose-lowering ef-
fect [23]. However, we did not measure serum levels of
active GLP-1 in the present study. In patients with dia-
betes, lowering levels of active lipoprotein lipase (which
is an insulin-dependent enzyme) promotes postprandial
hypertriglyceridemia and leads to increased levels of
small, dense LDLs that are oxidized readily. DPP-4
inhibitors improve postprandial hypertriglyceridemia
[24], so DPP-4 inhibitors could decrease oxLDL levels
by increasing the size and density of LDL-C.Furthermore, we speculate that the DPP-4 inhibitor
linagliptin decreases oxidative stress directly. Eight
patients received incretin therapy (Table 1) before
switching to linagliptin treatment. In these patients,
linagliptin caused a decrease in oxLDL levels from
99.4 ± 8.2 to 90.3 ± 6.5 U/L, suggesting that linagliptin
exerts anti-oxidative-stress effects beyond those mediated
by incretin.
Linagliptin is a unique, biliary-excreted DPP-4 inhibitor
with anti-oxidative-stress effects based upon its
xanthine structure [25], long half-life, and widespread
distribution in tissues [26]. These characteristics con-
tribute to decreased oxLDL levels. However, we did
not observe reduction of oxLDL levels upon linagliptin
treatment in insulin-treated patients, probably because
GA levels were increased after switching from insulin
to linagliptin. This finding suggests that excess hyper-
glycemia might elicit more powerful oxidative stress
than the anti-oxidative effects of linagliptin. Changes
in oxLDL levels observed in the present study were
within the normal range. However, a recent report
suggested that oxLDL > 48 U/L is associated with car-
diovascular risk factors [27]. Hence, we believe that
Table 3 Comparison between the non-insulin group before and
after treatment (n= 22)
Parameter Before After
BMI (kg/m2) n = 19 23.2 ± 1.0 23.3 ± 1.0
Systolic blood pressure (mmHg) n = 20 155.7 ± 6.3 162.3 ± 5.4
Diastolic blood pressure (mmHg) n = 20 78.7 ± 3.3 79.7 ± 3.0
Total protein (g/dL) 6.5 ± 0.1 6.6 ± 0.1
Albumin (g/dL) 3.7 ± 0.1 3.8 ± 0.1
AST (U/L) 14.9 ± 1.0 13.4 ± 1.2
ALT (U/L) n = 21 11.6 ± 1.4 10.1 ± 1.6
γ1.6 (U/L) 22.3 ± 3.0 23.2 ± 3.4
Total bilirubin (mg/dL) n = 17 0.35 ± 0.03 0.28 ± 0.02*
ALP (U/L) n = 21 251.0 ± 28.4 256.7 ± 25.8
LDH (U/L) n = 21 189.5 ± 6.0 179.2 ± 6.1
BUN (mg/dL) 54.5 ± 1.8 53.8 ± 2.3
Creatinine (mg/dL) 8.21 ± 0.34 8.28 ± 0.44
Total cholesterol (mg/dL) 162.6 ± 8.2 149.6 ± 6.9*
LDL-C (mg/dL) n = 21 83.1 ± 5.9 75.8 ± 5.0*
HDL-C (mg/dL) 46.9 ± 3.4 47.5 ± 3.5
Triglyceride (mg/dL) n = 21 119.7 ± 9.4 121.2 ± 11.9
CPR (ng/mL) n = 19 10.62 ± 1.20 11.56 ± 1.32
BG (mg/dL) 163.7 ± 9.2 162.7 ± 8.1
GA (%) 22.0 ± 0.8 21.2 ± 0.8
BNP (ng/mL) n = 21 429.2 ± 98.5 360.0 ± 79.3
hsCRP (mg/dL) n = 20 0.178 ± 0.046 0.193 ± 0.073
8OHdG (ng/mL) n = 12 0.356 ± 0.022 0.355 ± 0.041
*P < 0.05 compared with before treatment
Abbreviations are the same as shown for Table 2
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meaningful. In addition, we have reported that lina-
gliptin decreases urinary levels of 8OHdG in non-
diabetic mice after vascular injury [11]. Therefore, in
the present study, we measured plasma levels of
8OHdG, but differences in levels detected before and
after treatment were not observed. The different re-
sults between levels of oxLDL and 8OHdG might
be caused by the characteristics of markers of oxida-
tive stress. Several studies have reported that linaglip-
tin reduces levels of the lipid markers of oxidative
stress [28, 29], but there are several nucleic-acid
markers. Linagliptin is soluble in lipids, so it might
be predisposed to lipid oxidation. Furthermore, using
an animal model, we have observed reductions in
urinary levels of 8OHdG upon linagliptin treatment
[11]. However, the short half-life of 8OHdG in
serum might have complicated detection of changes
in its levels upon linagliptin treatment in the present
study.GA levels were not changed significantly by switch-
ing to linagliptin in the non-insulin-treated group.
DPP-4-inhibitor monotherapy has been shown to de-
crease the GA level by 2.9 % in drug-naïve Japanese
patients with type 2 diabetes undergoing HD [30, 31].
However, we did not observe reductions in GA levels
(probably because of the switch to linagliptin treatment)
but GA levels were increased greatly in the insulin-treated
group.
Chaykovska et al. reported that linagliptin decreases
cardiac gene expression of BNP in 5/6-nephrecto-
mized rats [32]. However, though there were no
changes in serum levels of BNP in insulin-treated pa-
tients, levels decreased in non-insulin-treated patients
(though this difference was not significant). When
proBNP in myocardial cells is secreted into the blood-
stream, it is broken down into NT-proBNP and
BNP1–32. DPP-4 cleaves BNP1–32 to produce BNP3–32
[33], which has low bioactivity. Consequently, the
diuretic and tissue-protective effects of BNP3–32 are
weaker than those of BNP1–32.
Levels of LDL-C and total cholesterol were decreased
significantly in the non-insulin-treated group. In clinical
trials, the DPP-4 inhibitor sitagliptin was also shown to
decrease LDL-C levels in Japanese patients with type 2
diabetes [34], suggesting that this lipid-lowering effect
is characteristic of this class of compound. This effect
was also observed in patients undergoing HD in the
present study.
The present study had limitations. First, the number of
patients was relatively low, and the number of patients
in the subgroup analysis was also too small. Second,
our study was not a head-to-head comparison. Finally,
it was not possible to evaluate parameters for some
patients. Hence, further work is warranted to validate
our findings.
Conclusion
Linagliptin lowered serum levels of oxLDL in patients
with type 2 diabetes who did not switch from insulin
treatment and who were undergoing HD. This action of
linagliptin was independent of its glucose-lowering effect.
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